Buprenorphine for Cancer Pain: Evidence, Guidelines, and Clinical Rationale for Early Use.

Abstract

As cancer survivorship increases, long-term opioid therapy (LTOT) has become more common in oncology, raising concerns about opioid-related harms. Buprenorphine offers unique pharmacologic advantages that position it as a safer alternative to full agonist opioids (FAOs), yet it remains underutilized in the management of cancer pain (CP). This article reviews the clinical rationale, supporting evidence, and practical considerations for using buprenorphine in managing CP throughout the cancer care continuum, with guidance from the NCCN Adult Cancer Pain Guideline Panel. This review synthesizes findings from pharmacologic research, clinical trials, guideline updates, and expert consensus. It examines the pharmacodynamics, dosing strategies, and safety of buprenorphine in vulnerable populations, as well as its potential to mitigate opioid-related complications. This review also discusses implementation barriers, including prescriber hesitancy, formulary restrictions, and stigma. Buprenorphine provides analgesia comparable to FAOs while reducing the risks of respiratory depression, opioid-induced hyperalgesia, hormonal disruption, and neurocognitive impairment. Buprenorphine may help reduce the neuroadaptive changes associated with LTOT, thereby preserving analgesic efficacy and improving long-term functional outcomes. Multiple formulations and flexible dosing options support personalized care, although regulatory restrictions and clinician unfamiliarity remain significant barriers. Buprenorphine is a viable yet underutilized option for managing CP, particularly when LTOT is anticipated. Broader clinical integration will require more precise guideline recommendations, clinician education, and policy reform. A paradigm shift toward early and proactive buprenorphine use could significantly improve safety, function, and quality of life in oncology patients.